Alector Inc. (ALEC)
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Alector NASDAQ: ALEC outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer's disease and two siRNA programs targeting tau and alpha-synuclein.
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.3 per share a year ago.
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.41 per share a year ago.
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.02 per share a year ago.
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector shares plunge after dementia drug fails to slow disease progression
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
